Regression of a cardiac rhabdomyoma in a patient receiving everolimus

Pediatrics

Volumn 127, Issue 5, 2011, Pages

  Tiberio, Dana ^a   Franz, David N ^b   Phillips, John R ^a  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Cardiac rhabdomyoma; Everolimus; mTOR inhibitor; Tuberous sclerosis

Indexed keywords

EVEROLIMUS;

ARTICLE; CASE REPORT; CHILD; DRUG BLOOD LEVEL; ECHOCARDIOGRAPHY; HEART RHABDOMYOMA; HEART TUMOR; HUMAN; MALE; PRIORITY JOURNAL; RHABDOMYOMA; SCHOOL CHILD; TREATMENT RESPONSE; TUMOR REGRESSION;

ABNORMALITIES, MULTIPLE; ASTROCYTOMA; CHILD; ECHOCARDIOGRAPHY, DOPPLER; FOLLOW-UP STUDIES; HEART NEOPLASMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; RHABDOMYOMA; SIROLIMUS; TREATMENT OUTCOME; TUBEROUS SCLEROSIS; TUMOR BURDEN;

EID: 79955498414     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2010-2910     Document Type: Article

References (6)

1. Orlova KA, Crino PB. The tuberous sclerosis complex. Ann N Y Acad Sci. 2010;1184: 87-105
2. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006;355(13):1345-1356
3. Franz DN, Leonard J, Tudor C, et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol. 2006; 59(3):490-498 (Pubitemid 43358069)
4. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008;358(2): 140-151
5. Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010;363(19):1801-1811
6. Kotulska K, Larysz-Brysz M, Grajkowska W, et al. Cardiac rhabdomyomas in tuberous sclerosis complex show apoptosis regulation and mTOR pathway abnormalities. Pediatr Dev Pathol. 2009;12(2):89-95